Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity

Expert Opinion on Drug Safety

Volumn 10, Issue 2, 2011, Pages 253-263

  Linares, Victoria ^a   Alonso, Virginia ^a   Domingo, José L ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

hepatotoxicity; infertility; lipid peroxidation; nephrotoxicity; oxidative stress; sulfasalazine

Indexed keywords

MESALAZINE; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; BLOOD DYSCRASIA; CROHN DISEASE; DRUG ABSORPTION; DRUG SAFETY; HEADACHE; HUMAN; LIPID PEROXIDATION; LIVER TOXICITY; MALE INFERTILITY; MEDLINE; NAUSEA; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PANCREATITIS; REVIEW; SKIN MANIFESTATION; SPERMATOZOON MOTILITY; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INFLAMMATORY BOWEL DISEASES; LIPID PEROXIDATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; SULFASALAZINE;

EID: 79952350508     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.529898     Document Type: Review

References (123)

1. Gisbert JP, Gonzalez-Lama Y, Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007;13:629-38 (Pubitemid 46799647)
2. Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs 2005;65:1825-49 (Pubitemid 41258139)
3. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;2:892-5
4. Brzezinski A, Rankin GB, Seidner DL, Lshner BA. Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Cleve Clin J Med 1995;62:317-19
5. Bonner GB, Ruderman WB. Inflammopharmacology. Kluwer Academic, Norwell, Massachusetts; 1993
6. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 2002;51:536-9
7. Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000;118:S68-82
8. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther 1972;181:555-62
9. Brans R, Laizane D, Khan A, Blomeke B. N-Acetyltransferase 2 genotyping: an acccurate and feasible approach for simultaneous detection of the most common NAT2 alleles. Clin Chem 2004;50:1264-6 (Pubitemid 38824245)
10. Schroder H, Campbell DE. Absorption, metabolism, and excretion of salicylazosulfapyridine in man. Clin Pharmacol Ther 1972;13:539-51
11. Das KM, Eastwood MA, McManus PA, Sircus W. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 1973;289:491-5
12. Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta Med Scand 1942;110:577-98
13. National Toxicology Program (NTP). Toxicology and carcinogenesis studies of salycilazosulphapyridine in F344/N Rats and B6C3F1 mice. National Toxicology Program Technical Report Series. 1997;457:15-21
14. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostagandins in ulcerative colitis, enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978;75:638-40 (Pubitemid 9025499)
15. Rogler G, Brand K, Vogl D, et al. Nuclear factor-kB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115:537-69
16. Robenbury RJ, Ganga A, Van Lent PL, et al. The anti-inflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages inducing apoptosis. Arthritis Rheum 2000;43:1941-50
17. Pruzauski W, Stefanski E, Vadas P, Ramamurthy NS. Inhibition of extracellular release of pro-inflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol 1997;53:1901-7 (Pubitemid 27356063)
18. Barrera P, Boerbooms AM, Van de Putte LBA, Van der Meer JWM. Effect of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996;25:234-53
19. Gan HT, Chen YQ, Ouyang Q. Sulfasalazine inhibits activation of nuclear factor-kappa B in patients with ulcerative colitis. J Gastroenterol Hepatol 2005;20:1016-24 (Pubitemid 40961223)
20. Gomez-Munoz A, O'Brien L, Salh B, Steinbrecher UP. 5-Aminosalicylate stimulates phospholipase D activity in macrophages. Biochimica et Biophysica Acta 2001;1533:110-18 (Pubitemid 32879387)
21. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101:1163-74 (Pubitemid 28125296)
22. Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 2002;47:471-88 (Pubitemid 34218873)
23. Levi AJ, Fisher AM, Hughes L, Henry WF. Male infertility due to sulphasalazine. Lancet 1979;314:276-8 (Pubitemid 9244105)
24. Toth A. Male infertility due to sulphasalazine. Lancet 1979;2:904
25. O'Morain C, Smethurst P, Dore CJ, Levi AJ. Reversible male infertility due to sulfasalazine: studies in man and rat. Gut 1984;25:1078-84 (Pubitemid 14002122)
26. Didolkar AK, Keizer-Zucker A, Sundaram K, Bardin CW. Effect of sulfasalazine and its analogs on fertility in male rats. Contraception 1988;37:539-48
27. Ueno T, Ishizu K, Baba Y, et al. Antifertility effect of the metabolites of sulfasalazine for male rats. Jpn J Fertil Steril 1990;35:715-20
28. Sharma RK, Kalla NR. Spermatozoal abnormalities and male infertility in the rat following sulfasalazine treatment. Int J Fertil 1994;39:347-54 (Pubitemid 24380487)
29. Marmor D. The effects of sulphasalazine on male fertility [review]. Reprod Toxicol 1995;9:219-23
30. Hoyt JA, Fisher LF, Swisher DK. Short-term male reproductive toxicity study with sulfasalazine in the rat. Reprod Toxicol 1995;9:315-26
31. Grieve J. Male infertility due to sulphasalazine. Lancet 1979;2:464 (Pubitemid 9250412)
32. Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 1981;22:445-51 (Pubitemid 11053277)
33. Di Paolo MC, Paoluzi OA, Pica R, et al. Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerante and side-effects. Digest Liver Dis 2001;33:563-9 (Pubitemid 32994629)
34. Fukushima T, Kato M, Adachi T, et al. Effects of sulfasalazine on sperm acrosome reaction and gene expression in the male reproductive organs of rats. Toxicol Sci 2005;85:675-82 (Pubitemid 40614297)
35. Fukushima T, Hamada Y, Komiyama M, et al. Early changes in sperm motility, acrosome reaction, and gene expression of reproductive organs in rats treated with sulfasalazine. Reprod Toxicol 2007;23:153-7 (Pubitemid 46215992)
36. Alonso V, Linares V, Belles M, et al. Sulfasalazine induced oxidative stress: a possible mechanism of male infertility. Reprod Toxicol 2009;27:35-40
37. Heetun ZS, Byrnes C, Neary P, O'Morain C. Review article: reproduction in the patient with inflammatory bowel disease [review]. Aliment Pharmacol Ther 2007;26:513-33 (Pubitemid 47174282)
38. Zelissen PM, van Hattum J, Poen H, et al. Influence of salazosulphapyridine and 5-aminosalicylic acid on seminal qualities and male sex hormones. Scand J Gastroenterol 1988;23:1100-4
39. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008;25:271-75
40. Norgard B, Czeizel AE, Rockenbauer M, et al. Population based case control study of the safety of sulfasalazine used during pregnancy. Aliment Pharmacol Ther 2001;15:483-86 (Pubitemid 32242773)
41. Mogadam M, Dobbins WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72-6 (Pubitemid 11213291)
42. Hernandez-Diaz S, Werler MM, Walker AM, Mitchel AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14 (Pubitemid 32162984)
43. Jarnerot G, Anderson S, Esbjorner E, Sandstrom B. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment of sulfasalazine. Scand J Gastroenterol 1981;16:1049-55 (Pubitemid 12236125)
44. Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulfasalazine during pregnancy and lactation. Acta Paediatr Scand 1987;76:137-42 (Pubitemid 17020978)
45. Hamling J, Raedler A, Helmchen U, Schreiber S. 5-Aminosalicylic acid associated renal tubular acidosis with decreased renal function in Crohn's disease. Digestion 1997;58:304-7 (Pubitemid 27270198)
46. Dwarakanath AD, Michael J, Allan RN. Sulphasalazine induced renal failure. Gut 1992;33:1006-1007
47. Schreiber S, Hamling J, Zehnter E, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997;40:761-6 (Pubitemid 27305469)
48. Molnar T, Farkas K, Nagy F, et al. Sulfasalazine-induced nephrotic syndrome in a patient with ulcerative colitis. Inflamm Bowel Dis 2009;16:552-3
49. Patel H, Barr A, Jeejeebhoy KN. Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 2009;23:170-6
50. Birketvedt GS, Berg KJ, Fausa O, Florholmen J. Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis. Inflamm Bowel Dis 2000;6:275-9
51. Augusto JF, Sayegh J, Simon A, et al. A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant 2009;24:2940-2
52. Miura N, Aoyama R, Kitagawa W, et al. Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment. Clin Nephrol 2009;71:74-9
53. Barbour VM, Williams PF. Nephrotic syndrome associated with sulphasalazine. BMJ 1990;301:818 (Pubitemid 20352604)
54. Sharma AK. Sulphasalazine and nephritic syndrome. Am J Gastroenterol 1993;88:1584
55. Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004;126:1733-9 (Pubitemid 38736338)
56. Schroeder KM. Role of mesalazine in acute and long-term treatment of ulceratice colitis and its complications [review]. Scand J Gastroenterol Suppl 2002;236:42-7
57. Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1-6 (Pubitemid 30058154)
58. Henning HV, Meinhold J, Eisenhauer T, et al. Chronic interstitial nephritis after treatment with 5-aminosalicylic acid. Dtsch Med Wochenschr 1989;114:1091 (Pubitemid 19182625)
59. Chester AC, Diamond LH, Schreiner GE. Hypersensitivity to salicylazosulfapyridine: renal and hepatic toxic reactions. Arch Intern Med 1978;138:1138-9 (Pubitemid 10220767)
60. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazineinduced interstitial nephritis. Neprol Dial Transplant 1996;11:614-21
61. Popoola J, Muller AF, Pollock L, et al. Late onset interstitial nephritis. Br Med J 1998;317:795-7
62. Tadic M, Grgurevic I, Scukanec-Spoljar M, et al. Acute interstitial nephritis due to mesalazine. Nephrology (Carlton) 2005;10:103-5 (Pubitemid 40776265)
63. Arend LJ, Springate JE. Interstitial nephritis from mesalazine: case report and literature review. Pediatr Nephrol 2004;19:550-3 (Pubitemid 38594297)
64. Calder IC, Funder CC, Green CR, et al. Nephrotoxic lesions from 5-aminosalicylic acid. BMJ 1972;1:52-4
65. Bilyard KG, Joseph EC, Metcalf R. Mesalazine: an overview of key preclinical studies. Scand J Gastroenterol Suppl 1990;172:52-5 (Pubitemid 20206668)
66. Diener U, Tuczek HV, Fischer C, et al. Renal function was not impaired by treatment with 5-aminosalicylic acid in rats and man. Naunyn Schmiedebergs Arch Pharmacol 1984;326:278-82
67. Green JR, Swan CH, Rowlinson A, et al. Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. Aliment Pharmacol Ther 1992;6:647-52
68. Green JR, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment Pharmacol Ther 1998;12:1207-16 (Pubitemid 28565960)
69. Hayllar J, Bjarnason I. Sulphasalazine in ulcerative colitis: in memoriam? Gut 1991;32:462-3
70. Nakajima H, Munakata A, Yoshida Y. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. J Gastroenterol 1995;30:115-17
71. Rubin R. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Am J Gastroenterol 1994;89:789-91 (Pubitemid 24132068)
72. Marinos G, Riley J, Painter DM, McCaughan GW. Sulfasalazine-induced fulminant hepatic failure. J Clin Gastroenterol 1992;14:132-5
73. McConkey B, Amos RS, Butler EP, et al. Salazopyrin in rheumatoid arthritis. Agents Actions 1994;43:202-5
74. Senturk T, Aydintug AO, Duzgun N, Tokgoz G. Seizures and hepatotoxicity following sulphasalazine administration. Rheumatol Int 1997;17:75-7 (Pubitemid 27364012)
75. Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with Sulfasalazine in inflammatory arthritis: a case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord 2008;9:48
76. Sotolongo RP, Neefe LI, Rudzki C, Ishak KG. Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity. Gastroenterology 1978;75:95-9 (Pubitemid 8378778)
77. Gulley RM, Mirza A, Kelly CE. Hepatotoxicity of salicylazosulfapyridine: a case report and review of the literature. Am J Gastroenterol 1979;72:561-4 (Pubitemid 10146385)
78. Smith MD, Gibson GE, Rowland R. Combined hepatotoxicity and neurotoxicity following sulphasalazine administration. Aust NZJ Med 1982;12:76-80 (Pubitemid 12078906)
79. Mennicke M, Zawodniak A, Keller M, et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant 2009;9:2197-202
80. Michel F, Navellou JC, Ferraud D, et al. DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis [review]. Joint Bone Spine 2005;72:82-5 (Pubitemid 40169972)
81. Bejia I, Ben Hammouda S, Riahi K, et al. DRESS syndrome induced by sulphasalazine in rheumatoid arthritis. Joint Bone Spine 2006;73:764-5 (Pubitemid 44918403)
82. Teo L, Tan E. Sulphasalazine-induced DRESS. Singapore Med J 2006;47:237-9
83. Aquino RT, Vergueiro CS, Magliari ME, de Freitas TH. Sulfasalazine- induced DRESS syndrome (Drug Rash with Eosinophilia and Systemic Symptoms). Sao Paulo Med J 2008;126:225-6
84. Kitas G, Farr M, Waterhouse L, Bacon PA. Influence of acetylator status on sulphasalazine efficacy and toxicity in patients with rheumatoid arthritis. Scand J Rheumatol 1992;21:220-5
85. Tanaka E, Taniguchi A, Urano W, et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol 2002;29:2492-9 (Pubitemid 35416951)
86. Tanigawara Y, Kita T, Aoyama N, et al. N-acetyltansferase 2 genotype-related sulfapyridine acetylation and its adverse events. Biol Pharm Bull 2002;25:1058-62 (Pubitemid 39663233)
87. Chen M, Xia B, Chen B, et al. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can J Gastroenterol 2007;21:155-8 (Pubitemid 47061612)
88. Punchard NA, Greenfield SM, Thompson RP. Mechanism of action of 5-arninosalicylic acid. Mediators Inflamm 1992;1:151-65
89. Rodriguez C, Mayo JC, Sainz RM, et al. Regulation of antioxidant enzymes, a significant role for melatonin, a minireview. J Pineal Res 2004;36:1-9 (Pubitemid 38130283)
90. Nicotera TM, Notaro J, Notaro S. Elevated superoxide dismutase in Bloom's syndrome, a genetic condition of oxidative stress. Cancer Res 1989;49:5239-43 (Pubitemid 19240453)
91. Gandy J, Millner GC, Bates HK, et al. Effects of selected chemicals on the glutathione status in the male reproductive system of rats. J Toxicol Environ Health 1990;29:45-57 (Pubitemid 20037239)
92. Aitken RJ. Sperm function tests and fertility. Int J Androl 2006;29:69-75
93. De Lamirande E, Gagnon C. Impact of reactive oxygen species on spermatozoa: a balancing act between beneficial and detrimental effects. Hum Reprod 1995;10:15-21
94. Pasqualotto FF, Sharma RK, Nelson DR, et al. Relationship between oxidative stress, semen characteristics, and clinical diagnosis in men undergoing infertility investigation. Fertil Steril 2000;73:459-64 (Pubitemid 30109638)
95. Fujii J, Iuchi Y, Matsuki S, Ishii T. Cooperative function of antioxidant and redox systems against oxidative stress in male reproductive tissues. Asian J Androl 2003;5:231-42 (Pubitemid 37107312)
96. Garrido N, Meseguer M, Simon C, et al. Pro-oxidative and antioxidative imbalance in human semen and its relation with male fertility. Asian J Androl 2004;6:59-65 (Pubitemid 38418340)
97. Kobayashi T, Miyazaki T, Natori M, Nozawa S. Protective role of superoxide dismutase in human sperm motility: superoxide dismutase activity and lipid peroxide in human seminal plasma and spermatozoa. Hum Reprod 1991;6:987-91
98. Belles M, Linares V, Albina ML, et al. Melatonin reduces uranium-induced nephrotoxicity in rats. J Pineal Res 2007;43:87-95 (Pubitemid 47039088)
99. Linares MV, Sanchez DJ, Belles M, et al. Pro-oxidant effects in the brain of rats concurrently exposed to uranium and stress. Toxicology 2007;236:82-91 (Pubitemid 46777071)
100. Sener G, Ozer Sehirli A, Altunbas HZ, et al. Melatonin protects against gentamicin-induced nephrotoxicity in rats. J. Pineal Res 2002;32:231-6 (Pubitemid 34478284)
101. Hara M, Yoshida M, Nishijima H, et al. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. J Pineal Res 2001;30:129-38 (Pubitemid 32245283)
102. Reiter RJ, Tan DX, Manchester LC, Tamura H. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. A review of the evidence. Cell Biochem Biophys 2001;34:237-56 (Pubitemid 33615836)
103. Sener G, Sehirli AO, Ayanoglu-Dulger G. Melatonin protects against mercury(II)-induced oxidative tissue damage in rats. Pharmacol Toxicol 2003;93:290-6 (Pubitemid 38096108)
104. Cetin H, Olgar S, Oktem F, et al. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycininduced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol 2007;34:1181-5 (Pubitemid 47416355)
105. De Jesus Soares T, Volpini RA, Francescato HD, et al. Effects of resveratrol on glycerol-induced renal injury. Life Sci 2007;81:647-56 (Pubitemid 47268017)
106. Hickey EJ, Raje RR, Reid VE, et al. Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. J Clin Endocrinol 2001;31:139-52 (Pubitemid 32607581)
107. Iraz M, Ozerol E, Gulec M, et al. Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin. Cell Biochem Funct 2006;24:357-61 (Pubitemid 44065240)
108. Boelsterli UA. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol Appl Pharmacol 2003;192:307-22 (Pubitemid 37311346)
109. Linares V, Alonso V, Albina ML, et al. Lipid peroxidation and antioxidant status in kidney and liver of rats treated with sulfasalazine. Toxicology 2009;256:152-6
110. Maldonado PD, Barrera D, Medina-Campos ON, et al. Aged garlic extract attenuates gentamicin induced renal damage and oxidative stress in rats. Life Sci 2003;73:2543-56 (Pubitemid 37098297)
111. Ghosh A, Sil PC. Anti-oxidative effect of a protein from Cajanus indicus L against acetaminophen-induced hepato-nephrotoxicity. J Biochem Mol Biol 2007;40:1039-49 (Pubitemid 350242292)
112. Yilmaz S, Atessahin A, Sahna E, et al. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology 2006;218:164-71 (Pubitemid 41821347)
113. Kovacic P, Cooksy A. Iminium metabolite mechanism for nicotine toxicity and addiction: oxidative stress and electron transfer. Med Hypotheses 2005;64:104-11 (Pubitemid 39469246)
114. Luqman S, Rizvi SI. Protection of lipid peroxidation and carbonyl formation in proteins by capsaicin in human erythrocytes subjected to oxidative stress. Phytother Res 2006;20:303-6
115. Nehru LB, Bansal MP6. Effect of selenium supplementation on the glutathione redox system in the kidney of mice after chronic cadmium exposures. J Appl Toxicol 1996;17:81-4 (Pubitemid 27091402)
116. Arthur JR. The glutathione peroxidases. Cell Mol Life Sci 2000;57:1825-35 (Pubitemid 32102578)
117. Beckett GJ, Hayes JD. Glutathione S-transferases: biomedical applications. Adv Clin Chem 1993;30:281-380
118. Hayes JD, Pulford DJ. The glutathione S-tranferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600
119. Boesch-Saadatmandi C, Loboda A, Jozkowicz A, et al. Effect of ochratoxin A on redox-regulated transcription factors, antioxidant enzymes and glutathione-S-transferase in cultured kidney tubulus cells. Food Chem Toxicol 2008;46:2665-71
120. Muruganandan S, Gupta S, Kataria M, et al. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology 2002;176:165-76
121. Pedraza-Chaverri J, Barrera D, Maldonado PD, et al. S- allylmercaptocysteine scavenges hydroxyl radical and singlet oxygen in vitro and attenuates gentamicin-induced oxidative and nitrosative stress and renal damage in vivo. BMC Clin Pharmacol 2004;4:5
122. Chiu PO, Leung HY, Ko KM. Schisandrin B enhances renal mitochondrial antioxidant status, functional and structural integrity, and protects against gentamicin-induced nephrotoxicity in rats. Biol Farm Bull 2008;31:602-5 (Pubitemid 351500488)
123. Muthukumaran S, Sudheer A, Menon VP, Nalini N. Protective effect of quercetin on nicotine-induced prooxidant and antioxidant imbalance and DNA damage in Wistar rats. Toxicology 2008;243:207-15 (Pubitemid 350250972)